FdaApplication
BLA 125268
Identifiers
- fda_app_no: BLA125268
Properties
| Property | Value |
|---|---|
| applicant_name | Amgen Inc. |
| application_type | BLA |
| approval_date | 2008-08-22 |
Revenue by product
NPLATE
| Period | Revenue |
|---|---|
| Q2 2026 | $430.0M |
| Q1 2026 | $412.0M |
| Q4 2025 | $385.0M |
| Q3 2025 | $457.0M |
| Q2 2025 | $369.0M |
| Q1 2025 | $313.0M |
| Q4 2024 | $337.0M |
| Q3 2024 | $456.0M |
| Q2 2024 | $346.0M |
| Q1 2024 | $317.0M |
| Q4 2023 | $386.0M |
| Q3 2023 | $419.0M |
| Q2 2023 | $310.0M |
| Q1 2023 | $362.0M |
| Q4 2022 | $469.0M |
| Q3 2022 | $288.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
NPLATE
| Period | Revenue |
|---|---|
| Q2 2026 | $430.0M |
| Q1 2026 | $412.0M |
| Q4 2025 | $385.0M |
| Q3 2025 | $457.0M |
| Q2 2025 | $369.0M |
| Q1 2025 | $313.0M |
| Q4 2024 | $337.0M |
| Q3 2024 | $456.0M |
| Q2 2024 | $346.0M |
| Q1 2024 | $317.0M |
| Q4 2023 | $386.0M |
| Q3 2023 | $419.0M |
| Q2 2023 | $310.0M |
| Q1 2023 | $362.0M |
| Q4 2022 | $469.0M |
| Q3 2022 | $288.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| NPLATE | ROMIPLOSTIM | 250MCG/0.5ML | INJECTABLE;SUBCUTANEOUS |
| NPLATE | — | 500MCG | For Injection |
| NPLATE | — | 125MCG | For Injection |
3 products